After carefully considering its promise and consulting with experts, Independence Blue Cross this year became the first major insurer to provide coverage for certain members who are seeking access to whole genome sequencing.
Xeroderma pigmentosum is a rare disease that leads to early skin cancer. New insights may lead to better prevention and survival for patients, as well as point to ways that UV-resistant gene functions could be used for skin cancer prevention and treatment.
While one German study has shown that population-wide screening for melanoma could dramatically reduce mortality, potential problems with the strategy include cost due to the overall rarity of the disease, patient compliance, and difficulties identifying patients likely to develop melanoma. Therefore, scientists are developing prediction models to identify those at high risk for melanoma, which can include genetic factors. Learn more